35481-04-0

Basic information

• Product Name: Benzenesulfonamide, N-(4-amino-2-methylphenyl)-4-methyl-
• CAS NO: 35481-04-0
• Molecular Formula: C14H16N2O2S
• Molecular Weight: 276.359
• Mol File: 35481-04-0.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Benzenesulfonamide, N-(4-amino-2-methylphenyl)-4-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenesulfonamide, N-(4-amino-2-methylphenyl)-4-methyl-(35481-04-0)
• EPA Substance Registry System: Benzenesulfonamide, N-(4-amino-2-methylphenyl)-4-methyl-(35481-04-0)

Safety Data

• Hazardous Substances Data: 35481-04-0(Hazardous Substances Data)

Upstream product

• 99-52-5 2-methyl-4-nitro-benzenamine 
• 98-59-9 p-toluenesulfonyl chloride 
• 97-15-4 4-methyl-N-(2-methyl-4-nitrophenyl)benzenesulfonamide 

Relevant articles and documents

Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia

A new series of diphenylpyrimidine derivatives (SFA-DPPYs) were synthesized by introducing a functional sulfonamide into the C-2 aniline moiety of pyrimidine template, and then were biologically evaluated as potent Bruton's tyrosine kinase (BTK) inhibitors. Among these molecules, inhibitors 10c, 10i, 10j and 10k displayed high potency against the BTK enzyme, with IC50 values of 1.18?nM, 0.92?nM, 0.42?nM and 1.05?nM, respectively. In particular, compound 10c could remarkably inhibit the proliferation of the B lymphoma cell lines at concentrations of 6.49?μM (Ramos cells) and 13.2?μM (Raji cells), and was stronger than the novel agent spebrutinib. In addition, the inhibitory potency toward the normal PBMC cells showed that inhibitor 10c possesses low cell cytotoxicity. All these explorations indicated that molecule 10c could serve as a valuable inhibitor for B-cell lymphoblastic leukemia treatment.

AROMATIC SULFONE COMPOUND AS ALDOSTERONE RECEPTOR MODULATOR

The present invention provides a compound represented by the following formula (I): [wherein, A represents a group of the following formula (A-1): etc., R1 and R2 each independently represent a hydrogen atom etc., Z represents CR3 etc., W represents CR4 etc., Q represents CR5 etc., R3, R4 and R5 each independently represent a hydrogen atom etc., Y represents an oxygen atom or sulfur atom, X represents an oxygen atom etc. and B represents an optionally substituted aryl group or optionally substituted heteroaryl group], the prodrug thereof or the pharmaceutically acceptable salt thereof for preventing or treating various diseases such as hypertesion, cerebral stroke, cardiac failure, etc.